Literature DB >> 21737558

Predicting survival in malignant mesothelioma.

A W Musk1, N Olsen, H Alfonso, A Reid, R Mina, P Franklin, J Sleith, N Hammond, T Threlfall, K B Shilkin, N H de Klerk.   

Abstract

Malignant mesothelioma (MM) of the pleura or peritoneum is a universally fatal disease attracting an increasing range of medical interventions and escalating healthcare costs. Changes in survival and the factors affecting survival of all patients ever diagnosed with MM in Western Australia over the past five decades and confirmed by the Western Australian Mesothelioma Registry to December 2005 were examined. Sex, age, date and method of diagnosis, site of disease and histological type were recorded. Date of onset of symptoms and performance status were obtained from clinical notes for a sample of cases. Cox regression was used to examine the association of the clinical variables and the 10-yr periods of disease onset with survival after diagnosis. Survival was inversely related to age, being worse for males (hazard ratio (HR) 1.4, 95% CI 1.2-1.6), and those with peritoneal mesothelioma (HR 1.4, 95% CI 1.1-1.7). Patients with sarcomatoid histology had worse prognosis than patients with epithelioid and biphasic histological subtypes. Survival improved after the 1970s and has made incremental improvements since then. Median (interquartile range) survival by decade, from 1960 until 2005, was 64 (0-198), 177 (48-350), 221 (97-504), 238 (108-502) and 301 (134-611) days; ~4 weeks of this apparent improvement can be attributed to earlier diagnosis. With increasing resources and treatment costs for MM over the past 40 yrs, there have been modest improvements in survival but no complete remissions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21737558     DOI: 10.1183/09031936.00000811

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  37 in total

Review 1.  Novel systemic therapy against malignant pleural mesothelioma.

Authors:  Michael R Mancuso; Joel W Neal
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 2.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

3.  Comparison of statistical methods for detection of serum lipid biomarkers for mesothelioma and asbestos exposure.

Authors:  Rengyi Xu; Clementina Mesaros; Liwei Weng; Nathaniel W Snyder; Anil Vachani; Ian A Blair; Wei-Ting Hwang
Journal:  Biomark Med       Date:  2017-05-23       Impact factor: 2.851

Review 4.  Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?"

Authors:  Vincenzo Di Noia; Emanuele Vita; Miriam Ferrara; Antonia Strippoli; Michele Basso; Giovanni Schinzari; Alessandra Cassano; Emilio Bria; Carlo Barone; Ettore D'Argento
Journal:  Curr Treat Options Oncol       Date:  2019-02-21

5.  Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.

Authors:  Roberta Carosio; Vincenzo Fontana; Luca Mastracci; Paola Ferro; Federica Grillo; Barbara Banelli; Pier Aldo Canessa; Paolo Dessanti; Antonella Vigani; Anna Morabito; Ulrich Pfeffer; Alessandro Poggi; Silvio Roncella; Maria Pia Pistillo
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-20       Impact factor: 4.553

6.  Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.

Authors:  Hidekazu Suzuki; Kazuhiro Asami; Tomonori Hirashima; Norio Okamoto; Tadahiro Yamadori; Motohiro Tamiya; Naoko Morishita; Takayuki Shiroyama; Sawa Takeoka; Akio Osa; Yuichiro Azuma; Kyoichi Okishio; Tomoya Kawaguchi; Shinji Atagi; Ichiro Kawase
Journal:  Lung       Date:  2013-10-20       Impact factor: 2.584

Review 7.  A Review of Pharmacologic Management in the Treatment of Mesothelioma.

Authors:  Eric P Borrelli; Conor G McGladrigan
Journal:  Curr Treat Options Oncol       Date:  2021-01-12

8.  Mutational analysis of hedgehog signaling pathway genes in human malignant mesothelioma.

Authors:  Chuan Bian Lim; Cecilia M Prêle; Hui Min Cheah; Yuen Yee Cheng; Sonja Klebe; Glen Reid; D Neil Watkins; Svetlana Baltic; Philip J Thompson; Steven E Mutsaers
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

9.  Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells.

Authors:  M A Hoda; J Münzker; B Ghanim; K Schelch; T Klikovits; V Laszlo; E Sahin; A Bedeir; A Lackner; B Dome; U Setinek; M Filipits; M Eisenbauer; I Kenessey; S Török; T Garay; B Hegedus; A Catania; S Taghavi; W Klepetko; W Berger; M Grusch
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

10.  Blocking the GITR-GITRL pathway to overcome resistance to therapy in sarcomatoid malignant pleural mesothelioma.

Authors:  Meilin Chan; Licun Wu; Zhihong Yun; Trevor D McKee; Michael Cabanero; Yidan Zhao; Mikihiro Kohno; Junichi Murakami; Marc de Perrot
Journal:  Commun Biol       Date:  2021-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.